Successful vaccine development for infectious diseases has largely been achieved in
settings where natural immunity to the pathogen results in clearance in at least some …

Therapeutic vaccines aim to modulate the immune system of HIV-infected individuals to elicit
sustained virologic control in the absence of antiretroviral therapy. Therapeutic vaccines that …

Developing a vaccine for human immunodeficiency virus (HIV) may be aided by a complete
understanding of those rare cases in which some HIV-infected individuals control replication …

HLA-B* 57 is the class I allele most consistently associated with control of human
immunodeficiency virus (HIV) replication, which may be linked to the specific HIV peptides …

The complex interplay between the host immune response and HIV has been the subject of
intense research over the last 25 years. HIV and simian immunodeficiency virus (SIV) CD8+ …

A global human immunodeficiency virus‐1 (HIV‐1) vaccine will have to elicit immune
responses capable of providing protection against a tremendous diversity of HIV‐1 variants …

The advent of reverse genetic approaches to manipulate the genomes of both positive (+)
and negative (−) sense RNA viruses allowed researchers to harness these genomes for …

Polymorphism in the HLA region of a chromosome is the major source of host genetic
variability in HIV-1 outcome, but there is limited understanding of the mechanisms …

An effective AIDS vaccine must control highly diverse circulating strains of human
immunodeficiency virus type 1 (HIV-1). Among HIV-1 gene products, the envelope (Env) …

Rhesus macaques (Macaca mulatta) are widely used in developing a strategy for
vaccination against human immunodeficiency virus by using simian immunodeficiency virus …